Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 3:19:421.
doi: 10.1186/s13054-015-1140-1.

Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study

Claire Delsuc  1 , Aurélie Cottereau  2 , Emilie Frealle  3 , Anne-Lise Bienvenu  4 , Rodrigue Dessein  5 , Sophie Jarraud  6   7 , Oana Dumitrescu  8   9 , Marion Le Maréchal  10 , Florent Wallet  11 , Arnaud Friggeri  12 , Laurent Argaud  13 , Thomas Rimmelé  14 , Saad Nseir  15   16 , Florence Ader  17   18   19
Affiliations

Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study

Claire Delsuc et al. Crit Care. .

Abstract

Introduction: Patients with advanced chronic obstructive pulmonary disease (COPD) are at risk for developing invasive pulmonary aspergillosis. A clinical algorithm has been validated to discriminate colonization from putative invasive pulmonary aspergillosis (PIPA) in Aspergillus-positive respiratory tract cultures of critically ill patients. We focused on critically ill patients with COPD who met the criteria for PIPA.

Methods: This matched cohort study included critically ill patients with COPD from two university hospital intensive care units (ICUs). We studied the risk factors for PIPA as well as the impact of PIPA on short- and long-term outcomes. Whether PIPA was associated with a pattern of bacterial colonization and/or infection 6 months before and/or during ICU stay was assessed. In addition, antifungal strategies were reviewed.

Results: Fifty cases of PIPA in critically ill patients with COPD in the ICU were matched with one hundred control patients with COPD. The ICU short- and the long-term (at 1 year) mortality were significantly increased in the PIPA group (p < 0.001 for all variables). PIPA was a strong independent risk factor for mortality in the ICU (odds ratio 7.44, 95 % confidence interval 2.93-18.93, p < 0.001) before vasopressor therapy, renal replacement therapy, and duration of mechanical ventilation. Before ICU admission, the use of corticosteroids and antibiotics significantly increased the risk of PIPA (p = 0.004 and p < 0.001, respectively). No significant difference in bacterial etiologic agents responsible for colonization and/or infection was found between the groups. Antifungal treatment was started in 64 % of PIPA cases, with a poor impact on the overall outcome.

Conclusions: PIPA was a strong death predictor in critically ill patients with COPD. The use of corticosteroids and antibiotics before ICU admission was a risk factor for PIPA. PIPA was not associated with a specific bacterial pattern of colonization or infection. Prompting antifungal treatment in critically ill patients with COPD who have PIPA may not be the only factor involved in prognosis reversal.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of selected cases. ABPA allergic bronchopulmonary aspergillosis, COPD chronic obstructive pulmonary disease, CPA chronic pulmonary aspergillosis, HM hematological malignancy, PIPA putative invasive pulmonary aspergillosis
Fig. 2
Fig. 2
Kaplan-Meier curves showing survival rate in patients with putative invasive pulmonary aspergillosis (PIPA) and control patients over a 3-month time course after intensive care unit admission. p < 0.001 by log-rank test
See this image and copyright information in PMC

References

    1. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine. 2000;79:250–60. doi: 10.1097/00005792-200007000-00006. - DOI - PubMed
    1. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant Associated Infection Surveillance Network (TRANSNET) Clin Infect Dis. 2010;50:1101–11. doi: 10.1086/651262. - DOI - PubMed
    1. Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007) Clin Microbiol Infect. 2011;17:1882–9. doi: 10.1111/j.1469-0691.2011.03548.x. - DOI - PubMed
    1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21. doi: 10.1086/588660. - DOI - PMC - PubMed
    1. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27–34. doi: 10.1164/rccm.200704-606OC. - DOI - PubMed

MeSH terms

Substances